Brandon Blue, MD

Cancer Focus:
Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma-Plasma Cell Disorders, Smoldering Multiple Myeloma (SMM), Waldenstrom Disease / Macroglobulinemia

Dr. Blue earned his MD at Meharry Medical College, Nashville, Tennessee. Dr. Blue completed an Internal Medicine Residency in the Department of Medicine at Washington University School of Medicine, St. Louis, Missouri, and d a Hematology/Oncology Fellowship in the Department of Medicine at Saint Louis University School of Medicine. Dr. Blue recently completed a Blood and Marrow Transplant and Cellular Immunotherapy Fellowship at Moffitt Cancer Center. Dr. Blue’s clinical interests include treatment of plasma cell disorders and evaluation of patients pre and post bone marrow transplant. His research interests include reducing health disparities and improving health outcomes for plasma cell dyscrasias.

Education & Training

Fellowship:

• Moffitt Cancer Center - Blood and Marrow Transplant and Cellular Immunotherapy
• Saint Louis University School of Medicine - Hematology/Oncology

Residency:

• Washington University School of Medicine - Internal Medicine

Medical School:

• Meharry Medical College - MD

Clinical Trial 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Noble JD, Peixoto BC, Menges MA, Abraham-Miranda J, Savid-Frontera C, Sawyer W, Sorathia VD, Cuadrado Delgado LA, Corallo SA, Llanos JC, Merritt EC, De Avila G, Castaneda-Puglianini OA, Liu HD, Alsina M, Nishihori T, Shain KH, Siqueira Silva AS, Baz RC, Blue BJ, Grajales-Cruz AF, Hansen DK, Cleveland JL, Perna F, Lynch CC, Binning JM, Atkins RM, Song X, Locke FL, Freeman CL. Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. Blood. 2026 Sep.148(11):1409-1422. Pubmedid: 42275255.
• Blue B, Lake P, Pidala J, Jim H, Locke FL, Vadaparampil S. Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. J Cancer Educ. 2026 May. Pubmedid: 42217135.
• Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, Wright C, Blue BJ, Baz RC, Shain KH, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Garcia-Pleitez H, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson LD, Julian K, Dima D, Banerjee R, Liang EC, Cassano Cassano R, Herr MM, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke FL, Hansen DK, Sborov D, Biran N, Grajales-Cruz A. Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2026 Mar.16(1). Pubmedid: 41896552. Pmcid: PMC13039266.
• Oswald LB, Li X, Ferraris CE, DeAvila G, Scheiber-Camoretti D, Gudenkauf LM, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker N, Carson TL, Vinci CE, Baz RC, Shain KH, Blue BJ, Grajales-Cruz AF, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini OA, Nishihori T, Liu HD, Locke FL, Jim HS, Hansen DK, Peres LC. Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity. Blood Adv. 2026 Mar.10(6):1959-1963. Pubmedid: 41564433. Pmcid: PMC12995473.
• Blue B, Lake P, Pidala J, Jim H, Locke FL, Vadaparampil S. Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. J Cancer Educ. 2026 Jun. Pubmedid: 42319704.
• Rees MJ, Cassano RC, Tan M, Zolotov E, Sidana S, Dima D, Kort J, Afrough A, Gaballa M, Pasvolsky O, Mikkilineni L, Khouri J, Raza S, Zanwar SS, Ferreri CJ, Kumar S, Khan AM, Atrash S, Portuguese AJ, Rana MS, Banerjee R, Freeman C, Blue B, Patel KK, Anderson LD, Puglianini OC, Shune LO, Biran N, Hansen DK, Lin Y. The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma. Am J Hematol. 2026 Jun.101(6):1314-1319. Pubmedid: 41862775.
• Oswald LB, Li X, Gudenkauf LM, De Avila G, Scheiber-Camoretti D, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker NH, Carson TL, Vinci CE, Baz RC, Shain KH, Blue B, Grajales-Cruz A, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini O, Nishihori T, Liu H, Locke FL, Jim HSL, Peres LC, Hansen DK. Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. Bone Marrow Transplant. 2026 Jul.61(7):864-872. Pubmedid: 42115674. Pmcid: PMC13349860.
• Blue BJ, ElHabr AK, Derman BA, Ray A, Ting J, Hasegawa K, Elsisi Z, Farajkhah K, Ayer T, Suvannasankha A. Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US. Clin Lymphoma Myeloma Leuk. 2026 Jul. Pubmedid: 42586901.
• Hammami MB, Haney SP, DeAvila D, Fadul J, Simonelli CE, Seitzler SC, Ravichandran S, Alsina M, Blue B, Grajales-Cruz A, Baz R, Shain KH. Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab. Am J Hematol. 2026 Jan.101(1):218-221. Pubmedid: 41211748.
• Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2026 Jan.147(5):497-512. Pubmedid: 40983035.
• Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica. 2026 Jan.111(1):184-195. Pubmedid: 40637727. Pmcid: PMC12775792.
• Gilbert O, Aiello J, Omel J, Price P, Davis A, Ortiz-Ravick LG, Gentry ED, Shah R, Soussou E, Blue B. Actionable Steps to Address Disparities in Healthcare Among US Patients With Multiple Myeloma: A Patient Perspective. J Cancer Educ. 2026 Jan. Pubmedid: 41543683.
• Abuhelwa Z, Amisha F, Fan W, De Avila G, Hansen DK, Grajales-Cruz AF, Blue B, Castaneda O, Liu H, Freeman CL, Nishihori T, Locke FL, Shain KH, Baz R, Alsina M. Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease. Front Oncol. 2025 Oct.15:1663814. Pubmedid: 41220935. Pmcid: PMC12597725.
• Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: 40229239. Pmcid: PMC11997198.
• Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
• Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: 38123069.
• Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
• Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: 37855718.
• Blue B, Pierre A, Mikhael J. Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Sep.23(9):651-659. Pubmedid: 37290997.
• Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
• Blue BJ, Brazauskas R, Chen K, Patel J, Hashmi S, Lehmann L, Bhatt N, Wood W, Saber W, Majhail N. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. Transplant Cell Ther. 2023 Nov.29(11):709.e1-709.e11. Pubmedid: 37482244.
• Blue B, Alomar M, Locke FL. Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative Therapy. JACC CardioOncol. 2023 Dec.5(6):755-757. Pubmedid: 38204996. Pmcid: PMC10774745.
• Bhutani M, Blue BJ, Cole C, Badros AZ, Usmani SZ, Nooka AK, Bernal-Mizrachi L, Mikhael J. Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer J. 2023 Dec.13(1):189. Pubmedid: 38110338. Pmcid: PMC10728116.
• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Peres LC, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton O, Alsina M, Brayer J, Blue B, Baz R, Siqueira Silva A, Nishihori T, Shain KH, Gillis N. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022 Jun.6(12):3767-3778. Pubmedid: 35500227. Pmcid: PMC9631567.
• Blue B. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transplant Cell Ther. 2022 Jul.28(7):345-346. Pubmedid: 35779944.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
• Fonseca JJ, Yeats AL, Blue B, Zalalutdinov MK, Brintlinger T, Simpkins BS, Ratchford DC, Culbertson JC, Grim JQ, Carter SG, Ishigami M, Stroud RM, Cress CD, Robinson JT. Enabling remote quantum emission in 2D semiconductors via porous metallic networks. Nat Commun. 2020 Jan.11(1):5. Pubmedid: 31911592. Pmcid: PMC6946668.
• Blue B, Vegunta R, Rodin M, Patolia S, Poddar N. Impact of an Inpatient Palliative Care Consultation in Terminally Ill Cancer Patients. Cureus. 2018 Jul.10(7):e3016. Pubmedid: 30254805. Pmcid: PMC6150761.
• Blue BJ, Luo S, Sanfilippo KM, Ganti A, Gumbel J, O'Brian K, Carson KR. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. Brit J Haematol. 2017 Jan.176(2):322-324. Pubmedid: 26887893.
• Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O'Brian K, Carson KR. Statins Are Associated With Reduced Mortality in Multiple Myeloma. J Clin Oncol. 2016 Nov.34(33):4008-4014. Pubmedid: 27646948. Pmcid: PMC5477827.

• Title: Artificial Intelligence for Widespread Awareness, Research and Education (AWARE): Establishing the Framework for Tailored AI Tools for Multiple Myeloma
  Award Number: 02259992658
  Sponsor: Moffitt Cancer Center
  Green, B. (PD/PI), Blue, B. (Co-PD/PI)